From: Cervical cancer heterogeneity: a constant battle against viruses and drugs
Trial identifier | Brief title | Actual Enrollment | Stage | Arm | Outcomes |
---|---|---|---|---|---|
NCT00002536 | Surgery with or without chemotherapy in treating patients with stage IB cervical cancer | 288 | IB | Arm I: RHPPL Arm II: NACT + RHPPL | Not statistically significant |
NCT00191100 | Comparative study of gemcitabine, cisplatin and radiation versus cisplatin and radiation in cancer of the cervix | 515 | IIB to IVA | Arm I: Gemcitabine + Cisplatin + Brachytherapy Arm II: Cisplatin + Brachytherapy | PFS (HR = 0.68; 95% CI = 0.49–0.95, p = 0.0227) and OS (HR = 0.68; 95% CI = 0.49–0.95, p = 0.0224) were improved in arm I vs arm II |
NCT00803062 | Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer | 452 | IVB, recurrent, or persistent | Arm I: Bevacizumab + Chemotherapy Arm II: Chemotherapy | Median OS was improved in arm I vs arm II (17.0 vs. 13.3 months, HR = 0.71; 98% CI = 0.54–0.95, p = 0.004) |
NCT00003945 | Comparison of three chemotherapy regimens in treating patients with stage IVB, recurrent, or persistent cervical cancer | 294 | IVB, recurrent, or persistent | Arm I: Cisplatin + Topotecan Arm II: Cisplatin | Median OS (9.4 vs. 6.5 months, P = 0.017) and PFS (4.6 vs. 2.9 months, P = 0.014) were improved in arm I vs arm II |
NCT00064077 | Comparison of four combination chemotherapy regimens using cisplatin in treating patients with stage IVB, recurrent, or persistent cancer of the cervix | 513 | IVB, recurrent, or persistent | Arm I: Paclitaxel + Cisplatin Arm II: Vinorelbine + Cisplatin Arm III: Gemcitabine + Cisplatin Arm IV: Topotecan + Cisplatin | Best OS (12.87 months) and PFS (5.82 months) in arm I |